Literature DB >> 23453478

Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients.

Marie Godfrin-Valnet1, Clément Prati, Marc Puyraveau, Eric Toussirot, Hélène Letho-Gyselink, Daniel Wendling.   

Abstract

OBJECTIVES: In patients with spondyloarthritis, to determine Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoffs matching the patient-acceptable symptom state (PASS) and patient-reported levels of disease activity, to assess associations between disease activity levels and presence of depression, and to identify ASDAS and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cutoffs indicating a flare and indicating a remission.
METHODS: Prospective single-center study of patients meeting ASAS criteria for spondyloarthritis receiving follow-up at the Besançon teaching hospital, France, between February 2011 and February 2012. In each patient, the BASDAI, ASDAS, Bath Ankylosing Spondylitis Functional Index (BASFI), patient-acceptable symptom state (PASS) and signs of depression were assessed. Receiver-operating characteristic (ROC) curves were drawn to identify the ASDAS cutoffs separating different levels of disease activity. The kappa coefficient was computed to evaluate agreement between patients and physicians regarding the presence of flares.
RESULTS: Two hundred patients with a mean age of 44.4 ± 12.5 years and mean disease duration of 12.9 ± 10.5 years were included. Mean BASDAI was 4.1 ± 2.2, mean ASDAS-C-reactive protein (CRP) was 2.4 ± 1, mean BASFI was 3.3 ± 2.7, and 58.9% of patients reported being in the PASS. The PASS was associated with BASDAI values inferior or equal to 4.1 and ASDAS-CRP values inferior or equal to 2.3. Mild patient-reported disease activity was associated with BASDAI values inferior or equal to 3.8 and ASDAS-CRP values inferior or equal to 2.3; corresponding values for high patient-reported disease activity were superior to 5.2 and superior to 3.1. Among patients reporting high disease activity, 64.5% had Beck Depression Inventory scores consistent with severe depression. At the time of the visit, 36.9% of the patients and 28.3% of the physicians felt there was a flare. Cutoffs indicating a flare were superior or equal to 5.2 for the BASDAI and superior or equal to 2.3 for the ASDAS-CRP. Agreement between patients and physicians regarding flares was good (Kappa, 0.61). An evaluation in 43 patients indicated that an ASDAS-CRP cutoff inferior or equal to 2.2 separated the 25.6% of patients who reported being in remission from the other patients.
CONCLUSION: Our results show a significant association between disease activity and depression severity, as well as good agreement between BASDAI and ASDAS. The ASDAS cutoffs for the various levels of patient-reported disease activity differed from the cutoffs suggested by ASAS; a 2.3 cutoff was found for both patient-reported absence of disease activity and PASS, indicating that achieving PASS should be included among our treatment objectives.
Copyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  ASDAS; BASDAI; Disease activity cutoffs; Flare; PASS; Patient-reported outcomes; Spondylarthritis

Mesh:

Substances:

Year:  2013        PMID: 23453478     DOI: 10.1016/j.jbspin.2013.01.003

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  12 in total

1.  Spondyloarthritis: Is it time to replace BASDAI with ASDAS?

Authors:  Pedro Machado; Robert Landewé
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

2.  Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.

Authors:  Nemanja Damjanov; Waleed Al Shehhi; Feng Huang; Sameer Kotak; Ruben Burgos-Vargas; Khalid Shirazy; Eustratios Bananis; Annette Szumski; Lyndon J Q Llamado; Ehab Mahgoub
Journal:  Rheumatol Int       Date:  2016-03-11       Impact factor: 2.631

Review 3.  Treat to Target in Axial Spondyloarthritis: What Are the Issues?

Authors:  Abhijeet Danve; Atul Deodhar
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

4.  The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis.

Authors:  Yi-Hsing Chen; Wen-Nan Huang; Yi-Ming Chen; Kuo-Lung Lai; Tsu-Yi Hsieh; Wei-Ting Hung; Ching-Tsai Lin; Chih-Wei Tseng; Kuo-Tung Tang; Yin-Yi Chou; Yi-Da Wu; Chin-Yin Huang; Chia-Wei Hsieh; Yen-Ju Chen; Yu-Wan Liao; Hsin-Hua Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-16

5.  Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS).

Authors:  Dilek Solmaz; Tulay Yildirim; Okan Avci; Nazmiye Tomas; Servet Akar
Journal:  Clin Rheumatol       Date:  2015-12-16       Impact factor: 2.980

6.  Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care.

Authors:  Fausto Salaffi; Marina Carotti; Marwin Gutierrez; Marco Di Carlo; Rossella De Angelis
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

7.  Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab.

Authors:  Mariagrazia Lorenzin; Augusta Ortolan; Paola Frallonardo; Francesca Oliviero; Leonardo Punzi; Roberta Ramonda
Journal:  BMC Musculoskelet Disord       Date:  2015-07-24       Impact factor: 2.362

8.  Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis.

Authors:  Isabel Castrejón; Theodore Pincus; Daniel Wendling; Maxime Dougados
Journal:  RMD Open       Date:  2016-07-07

9.  Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study.

Authors:  Charlotte Jacquemin; Anna Molto; Hervé Servy; Jérémie Sellam; Violaine Foltz; Frédérique Gandjbakhch; Christophe Hudry; Stéphane Mitrovic; Benjamin Granger; Bruno Fautrel; Laure Gossec
Journal:  RMD Open       Date:  2017-06-29

10.  Gene Expression Analysis before and after Treatment with Adalimumab in Patients with Ankylosing Spondylitis Identifies Molecular Pathways Associated with Response to Therapy.

Authors:  Marzia Dolcino; Elisa Tinazzi; Andrea Pelosi; Giuseppe Patuzzo; Francesca Moretta; Claudio Lunardi; Antonio Puccetti
Journal:  Genes (Basel)       Date:  2017-04-24       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.